Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference [Yahoo! Finance]
Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference
Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease
Coya Therapeutics, Inc. (NASDAQ: COYA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $18.00 price target on the stock.
Coya Therapeutics to Present at Upcoming Healthcare Conferences [Yahoo! Finance]